No Picture
Trading Ideas

GlaxoSmithKline, Vir Biotech Team Up in Hunt For Coronavirus Treatment

British drugmaker GlaxoSmithKline (GSK) and Vir Biotechnology Inc (VIR) on Monday announced a partnership to develop potential antibody treatments for COVID-19, the disease caused by the coronavirus.As part of the collaboration agreement GSK will make an investment in Vir of $250 million, priced at $37.73, representing a 10% premium to the closing share price on March 27, 2020, according to the announcement. Vir’s shares soared as much as 34% rising to around $39 in early U.S. trading following the news of GSK’s investment.Wall Street analysts take a cautious stance on Vir’s stock. The Hold analyst consensus rating is based on …read more […]

No Picture
Trading Ideas

This Penny Stock Joins the Fight Against Coronavirus; Analyst Sees Triple-Digit Upside

With a market cap of a miniscule $10.16 million, you can firmly place biotech Capricor Therapeutics (CAPR) in the nano cap section. Although, according to one analyst, if recent developments are anything to go by, the Beverly Hills, California based company won’t be in the small fry category for much longer.H.C. Wainwright’s Joseph Pantginis reiterated a Buy on Capricor along with a $9.00 price target. The implication for investors? Potential upside of a humungous 737%. (To watch Pantginis’s track record, click here)So, what is driving an analyst to set such an extravagant target for such a tiny player? Well, among …read more […]

No Picture
Business News

Alaska’s RavnAir bankruptcy while awaiting government aid shows regional airlines’ challenges

RavnAir Group, the largest regional carrier in Alaska, filed for bankruptcy on Sunday and grounded all of its 72 planes, saying it was clear that government aid would not arrive before it ran out of cash in the midst of an “astonishing” decline in bookings and revenue due to the coronavirus.

…read more […]